Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Dec;407(8):3631-3642.
doi: 10.1007/s00423-022-02704-4. Epub 2022 Oct 17.

Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study

A Ríos  1   2 , M A Rodríguez  3 , J A Puñal  4 , P Moreno  5 , E Mercader  6 , E Ferrero  7 , J Ruiz-Pardo  8 , M A Morlán  9 , J Martín  10 , M Durán-Poveda  11   12 , J M Bravo  13 , D Casanova  14 , M P Salvador Egea  15 , N M Torregrosa  16 , A Exposito-Rodríguez  17 , G Martínez-Fernández  18 , A M Carrión  19 , O Vidal  20 , F Herrera  21 , G Ruiz-Merino  22 , J M Rodríguez  23   3
Affiliations
Observational Study

Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study

A Ríos et al. Langenbecks Arch Surg. 2022 Dec.

Abstract

Purpose: Familial papillary thyroid microcarcinoma (FPTMC) can present a more aggressive behavior than the sporadic microcarcinoma. However, few studies have analyzed this situation. The objective is to analyze the recurrence rate of FPTMC and the prognostic factors which determine that recurrence in Spain.

Methods: Spanish multicenter longitudinal analytical observational study was conducted. Patients with FPTMC received treatment with curative intent and presented cure criteria 6 months after treatment. Recurrence rate and disease-free survival (DFS) were analyzed. Two groups were analyzed: group A (no tumor recurrence) vs. group B (tumor recurrence).

Results: Ninety-four patients were analyzed. During a mean follow-up of 73.3 ± 59.3 months, 13 recurrences of FPTMC (13.83%) were detected and mean DFS was 207.9 ± 11.5 months. There were multifocality in 56%, bilateral thyroid involvement in 30%, and vascular invasion in 7.5%; that is to say, they are tumors with histological factors of poor prognosis in a high percentage of cases. The main risk factors for recurrence obtained in the multivariate analysis were the tumor size (OR: 2.574, 95% CI 1.210-5.473; p = 0.014) and the assessment of the risk of recurrence of the American Thyroid Association (ATA), both intermediate risk versus low risk (OR: 125, 95% CI 10.638-1000; p < 0.001) and high risk versus low risk (OR: 45.454, 95% CI 5.405-333.333; p < 0.001).

Conclusion: FPTMC has a recurrence rate higher than sporadic cases. Poor prognosis is mainly associated with the tumor size and the risk of recurrence of the ATA.

Keywords: Familial papillary microcarcinoma; Familial papillary thyroid carcinoma; Papillary thyroid carcinoma; Papillary thyroid microcarcinoma; Recurrence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Disease-free survival (DFS) of familial papillary thyroid microcarcinoma. A Mean DFS. B DFS according to the diffuse sclerosing variant. C DFS according to the vascular invasion. D DFS according to the lymphatic involvement. E DFS according to “T” of the 7th edition of the TNM Staging System of the American Joint Committee on Cancer. F DFS according to “N” of the 7th edition of the TNM Staging System of the American Joint Committee on Cancer. G DFS according to the tumor stage of the 7th edition of the TNM Staging System of the American Joint Committee on Cancer. H DFS according to “T” of the 8th edition of the TNM Staging System of the American Joint Committee on Cancer. I DFS according to “N” of the 8th edition of the TNM Staging System of the American Joint Committee on Cancer. J DFS according to the tumor stage of the 8th edition of the TNM Staging System of the American Joint Committee on Cancer. K DFS according to the assessment of risk of recurrence of the American Thyroid Association
See this image and copyright information in PMC

References

    1. Rios A, Torregrosa B, Rodríguez JM, et al. Ultrasonographic risk factors of malignancy in thyroid nodules. Langenbecks Arch Surg. 2016;401:839–849. doi: 10.1007/s00423-016-1451-y. - DOI - PubMed
    1. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. EJSO. 2018;44:307–315. doi: 10.1016/j.ejso.2017.03.004. - DOI - PubMed
    1. Miyauchi A. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J Surg. 2016;40:516–522. doi: 10.1007/s00268-015-3392-y. - DOI - PMC - PubMed
    1. Ríos A, Rodríguez JM, Navas D, et al. Family screening in familial papillary carcinoma: the early detection of thyroid disease. Ann Surg Oncol. 2016;23:2564–2570. doi: 10.1245/s10434-016-5149-8. - DOI - PubMed
    1. Navas-Carrillo D, Ríos A, Rodríguez JM, Parrilla P, Orenes-Piñero E. Familial non medullary thyroid cancer: screening, clinical, molecular and genetic findings. Biochim Biophys Acta. 2014;1846:468–476. doi: 10.1016/j.bbcan.2014.09.002. - DOI - PubMed

Publication types

Supplementary concepts